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Abstract
Background: The goal of iodine-131 therapy for pediatric Graves’ disease is to induce hypothyroidism. However,
changes in post-treatment thyroid volume have not been investigated in pediatric and/or adolescent patients.
Objective: The aim of this retrospective study was to examine whether changes in thyroid volume predict post-
treatment hypothyroidism in adolescent Graves’ disease patients.
Patients and Methods: We used ultrasonography to examine changes in thyroid volume, and also assessed
thyroid functions, at 0, 1, 3, 5, 8 and 12 months after iodine-131 treatment in 49 adolescents ranging in age from
12 to 19 years retrospectively. Based on thyroid function outcome at 12 months, patients were divided into two
groups: 29 patients with overt hypothyroidism requiring levothyroxine replacement and 20 without overt
hypothyroidism. We compared changes in post-radioiodine thyroid volume between the two groups.
Results: About 90% of patients whose thyroid volume at 3 months after iodine-131 administration was less than
50% of the original volume were hypothyroid by one year after treatment (positive predictive value 88%, sensitivity
75.9%, specificity 85.0%).
Conclusions: We believe ultrasonographic measurement of thyroid volume at 3 months after iodine-131 to be
clinically useful for predicting post-treatment hypothyroidism in adolescent Graves’ disease patients.
Introduction
Graves’ disease (GD) is the most common cause of
hyperthyroidism in children, adolescents and adults [1-3].
Treatments available for GD include anti-thyroid medica-
tions (methimazole or propylthiouracil), surgery and
radioactive iodine (RAI) [4,5]. There is ongoing debate
worldwide regarding the most suitable therapy for GD in
pediatric patients. Although anti-thyroid medications are
commonly used as first-line therapy for pediatric GD,
long-term remission occurs in only 20% to 30% of pubertal
cases and 15% of pre-pubertal cases treated pharmacologi-
cally [3,6-8]. Consequently, either surgery or RAI is
needed to achieve a long-term cure in most pediatric GD
patients.
RAI therapy is generally considered to be safe, inexpen-
sive and effective, with relatively few side effects [8-10].
Radioiodine was introduced for the treatment of GD
more than 50 years ago [11], and at present is the most
commonly used treatment for adult GD in the North
America [12]. In 107 young GD patients who had been
treated with RAI before age 20 years, no increased risk of
adverse events was reported [13]. In some facilities, RAI
is becoming the first-line therapy for GD in children and
adolescents [14,15].
The goal of iodine-131 therapy for pediatric GD is to
induce hypothyroidism [16,17]. When children are treated
with 330 μCi/g of iodine-131, hypothyroidism is achieved
in nearly 95% of patients [18]. Higher dose ablative therapy
(13.8 to 15.6 mCi) is effective in nearly all children with
GD [19]. The use of high dose iodine-131 will destroy
most thyroid tissue, thereby decreasing the risk of * Correspondence: nakatake@j-tajiri.or.jp
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cially in children [20]. The long-term risks of thyroid can-
cer appear to be lower when the thyroid gland is largely
ablated than when residual thyroid tissue remains [21,22].
Changes in post-RAI thyroid volume have been investi-
gated in adult GD patients [10,23-26], but not in pediatric
and/or adolescent patients [3].
The objective of this retrospective study was to inves-
tigate changes in post-radioiodine thyroid volume in
adolescent GD patients (< 20 years old) and also to
examine whether these changes predict post-treatment
hypothyroidism.
Patients and Methods
The medical records of all adolescent patients (< 20
years old) at Tajiri Thyroid Clinic who received a single
RAI treatment for GD during the decade from January
2000 to January 2010 were examined retrospectively.
The present study was approved by the Institutional
Review Board of our clinic.
G Dw a sd i a g n o s e db a s e do ne l e v a t e df r e et h y r o x i n e
and suppressed thyrotropin concentrations, elevated
TSH receptor antibodies (TRAb), and diffuse, elevated
uptake of radioiodine or technetium-99 m within the
thyroid. Thyrotropin, free thyroxine and TSH receptor
antibody were measured by electrochemiluminescence
immunoassay (Cobas e601; Roche Diagnostics, Tokyo,
Japan).
The iodine-131-absorbed radiation dose was calculated
from RAIU and thyroid weight, using the formula: dose
(μCi/g) = oral iodine-131 dose (mCi) × estimated 24 h
RAIU (%) × 10/thyroid weight (g). Twenty-four hour RAI
uptake was estimated using 4-hour uptake of iodine-123
[27] or 20-minute uptake of technetium-99 m [28]. Thyr-
o i dv o l u m ew a se s t i m a t e db yu l t r a s o u n d( S S A - 3 5 0 A ;
Toshiba Inc. Ltd., Tokyo, Japan) as previously reported
[29]. Thyroid function (free thyroxine and thyrotropin)
and ultrasonographic thyroid volume were determined at
1, 3, 5, 8 and 12 months after RAI therapy. When free
thyroxine values dropped below 0.8 ng/dL and/or thyro-
tropin levels rose above 20 μIU/mL, replacement therapy
with levothyroxine was initiated.
Statistical analyses were performed using Student’s t test
and the chi-squared test. Values are shown as means ±
standard deviation (SD). A P-value of less than 0.05 was
considered to indicate a statistically significant difference.
Results
There were 10 males and 39 females ranging in age from
12 to 19 years (mean ± SD, 16.4 ± 1.8 years old). All 49
patients were initially treated with anti-thyroid medica-
tions for 1 to 108 months (80% with methimazole, 20%
with propylthiouracil). RAI therapy was performed due
to lack of remission after 14 to 108 months (39%) of
medical treatment, the development of a presumed toxic
reaction to anti-thyroid drugs (44%; rash, arthralgia,
hepatitis, neutropenia), or a desire for definitive therapy
(17%). Anti-thyroid drugs were discontinued 3 to 5 days
before RAI treatment. After administration of iodine-131,
patients were treated with anti-thyroid drugs with or
without propranolol to control symptoms of hyperthyr-
oidism until hyperthyroxinemia abated.
The mean RAI dose for our 49 patients was 184 ±
84 μCi/g (range 44 - 393 μCi/g) and mean thyroid volume
decreased significantly from 34.5 ml to 8.3 ml during the
one year period after RAI (P < 0.00001). Based on thyroid
functions at one year after RAI, patients were divided into
two groups: 29 (59.2%) with overt hypothyroidism
(hypothyroid patients) requiring levothyroxine replace-
ment therapy (mean time until hypothyroidism: 4 ±
1.5 months, range 1 - 8 months) and 20 (40.8%) without
hypothyroidism (non-hypothyroid patients) taking no
medication at one year after RAI. The 20 non-hypothyroid
patients consisted of 8 euthyroid and 12 hyperthyroid
patients. Euthyroid patients included two who experienced
transient hypothyroidism at 3 months after I-131 but had
recovered without intervention at 1 year and one with sub-
clinical hypothyroidism (TSH 6.53 μIU/ml (normal range:
0.20 - 3.30 μIU/ml)) at 1 year. Hyperthyroidism was sub-
clinical in 8 patients and mild in 4 with serum free T4
levels of 1.93 - 2.03 ng/dl (normal range: 0.90 - 1.80 ng/
dl). None of the hyperthyroid patients took anti-thyroid
drugs at one year after RAI because all were asympto-
matic. There were no statistically significant differences
between euthyroid and hyperthyroid patients with respect
to pre- and post-treatment thyroid volumes, or in percent
volume reductions at 1, 3, 5, 8 and 12 months. The char-
acteristics of adolescent GD patients who received RAI
therapy, divided into hypothyroid and non-hypothyroid
groups, are summarized in Table 1. There were no signifi-
cant differences between the two groups in gender (P =
0.20), age (P = 0.18), pre-treatment thyroid volume (P =
0.30) or pre-treatment TRAb values measured by cosmic
TRAb coated-tube kit (P = 0.45). The two groups differed
only in the RAI dose administered (P = 0.048).
We compared changes in post-RAI administration
thyroid volume during the one year period after treat-
ment between hypothyroid and non-hypothyroid
patients. As shown in Figure 1, post-treatment thyroid
volume was significantly smaller in hypothyroid than in
non-hypothyroid patients, especially after 8 months (8.2
ml vs. 13.1 ml at 8 months; P = 0.003, 6.3 ml vs. 10.9
ml at 12 months; P = 0.0005). The mean percent reduc-
tion in thyroid volume was significantly greater in
hypothyroid than in non-hypothyroid patients at all
measurement time points (P < 0.005) (Figure 2). We
examined whether changes in thyroid volume predict
post-treatment hypothyroidism at one year. The optimal
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ism is considered to be a 50% reduction, as compared to
t h eo r i g i n a lv o l u m eo ft h et h y r o i dg l a n d ,a t3m o n t h s
after iodine-131 administration (Table 2). The sensitiv-
ity, specificity, positive predictive value, negative predic-
tive value, positive likelihood ratio, and negative
likelihood ratio were 75.9%, 85.0%, 88.0%, 70.8%, 5.1
and 0.3, respectively.
We also examined the relationship between iodine-131
doses and post-RAI administration thyroid volume at 3
months in all 49 patients. Three iodine-131 doses (mean ±
SD) were compared: 120 ± 32 μCi/g (n = 25, range 44 -
171 μCi/g), 200 ± 20 μCi/g (n = 11, range 174 - 224 μCi/
g) and 300 ± 62 μCi/g (n = 13, range 225 - 393 μCi/g).
When doses of 120 μCi/g, 200 μCi/g and 300 μCi/g were
used, post-RAI administration thyroid volumes at 3
months were less than 50% of the pre-treatment thyroid
volume in 36% (9/25), 55% (6/11) and 85% (11/13) of
patients, respectively. We also found that doses of
120 μCi/g, 200 μCi/g and 300 μCi/g resulted in hypothyr-
oidism at 1 year after RAI in 48% (12/25), 55% (6/11) and
85% (11/13) of the patients, respectively.
Table 1 Characteristics of Adolescent GD Patients Receiving Iodine-131 Therapy
Hypothyroid
(n = 29)
Non-hypothyroid (n = 20) P-value
Gender, female/male 20/9 19/1 NS (0.06)
Age (yr) 16.1 ± 1.9 16.8 ± 1.6 NS (0.18)
Pre-treatment thyroid volume (ml) 36.3 ± 17.5 31.9 ± 11.6 NS (0.30)
Pre-treatment TRAb
(%)
60.2 ± 27.8
(n = 22)
53.5 ± 29.1 NS (0.45)
I-131 dose (μCi/g) 202.7 ± 88.6 156.3 ± 71.2 0.048
NS: not significant. All values are means ± SD.
Figure 1 Changes in thyroid volume during the one year period after iodine-131 therapy in hypothyroid and non-hypothyroid
patients. Mean thyroid volumes in hypothyroid vs. non-hypothyroid patients were 36.3 ml vs. 31.9 ml at 0 months (m), 20.3 ml vs. 23.2 ml at 1
m, 13.6 ml vs. 18.8 ml at 3 m, 10.9 ml vs. 14.8 ml at 5 m, 8.2 ml vs. 13.1 ml at 8 m, and 6.3 ml vs. 10.9 ml at 12 m after iodine-131 therapy.
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This retrospective study showed mean post-treatment
thyroid volume to be significantly decreased, from 34.5
ml to 8.3 ml (P < 0.00001), at one year after RAI in 49
adolescent GD patients (age range: 12 - 19 years), as has
been demonstrated in adult GD patients (10,23-26).
The goal of iodine-131 therapy for pediatric GD is to
ablate the thyroid gland, in order to decrease the risk of
RAI-induced thyroid tumors [18]. However, changes in
post- RAI administration thyroid volume have not been
investigated in pediatric and/or adolescent patients [3]. We
found thyroid volume at one year after RAI administration
Figure 2 Percent reductions in thyroid volume during the one year period after iodine-131 therapy in hypothyroid and non-
hypothyroid patients. Mean percent reductions in thyroid volume in hypothyroid vs. non-hypothyroid patients were 42.6% vs. 24.2% at 1
month (m), 61.2% vs. 37.6% at 3 m, 70.1% vs. 46.5% at 5 m, 76.6% vs. 56.9% at 8 m, and 82.2% vs. 62.4% at 12 m after iodine-131 therapy.
Table 2 Sensitivity and Specificity of Percent Reductions in Thyroid Volume at Each Measurement Time Point after
Iodine-131 Therapy
Month(s) after iodine-131 therapy
1358 1 2
% reduction* Sens Spec Sens Spec Sens Spec Sens Spec Sens Spec
30% 75.9 55.0
40% 55.2 80.0 79.3 60.0
50% 41.4 95.0 75.9 85.0 92.6 53.3
60% 55.2 90.0 73.3 74.1 96.2 57.9
70% 51.9 93.3 73.1 78.9 85.2 60.0
80% 46.2 94.7 74.1 85.0
90% 18.5 100.0
*% reduction: cut-off point for percent reduction in thyroid volume
Sens: sensitivity for predicting hypothyroidism at one year after iodine-131 therapy using %reduction
Spec: specificity for predicting hypothyroidism at one year after iodine-131 therapy using %reduction
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smaller in hypothyroid than in non-hypothyroid patients
(mean 6.3 ml vs. 10.9 ml; P < 0.001). As the post- RAI
administration thyroid volume is smaller in hypothyroid
patients, apparently conferring a lower risk of thyroid neo-
plasm development, this underscores the need for
hypothyroidism to be a goal of therapy when using iodine-
131 to treat GD in children [18].
A correlation between changes in thyroid volume and
thyroid function outcome in adult patients with GD has
been described (10,23-25). However, these studies did
not investigate the relationship between the degree of
thyroid volume reduction and thyroid function outcome.
Chiovato et al reported that the degree of thyroid volume
reduction after RAI administration was the best predictor
of early (within 1 year) thyroid function outcome in adult
Graves’ hyperthyroidism [26]. In fact, we found that
about 90% of our patients had become hypothyroid at
one year when thyroid volume was less than 50% of the
original volume at 3 months after iodine-131 administra-
tion (positive predictive value 88%, sensitivity 75.9%, spe-
cificity 85.0%).
We also found that 85% of patients treated with a dose
of 300 μCi/g (range: 225 - 393 μCi/g) showed remarkable
thyroid gland shrinkage (< 50% of the original thyroid
gland volume at 3 months) and 85% were hypothyroid at
one year. These data indicate that doses of approximately
300 μCi/g are needed to insure ablation of thyroid tissue.
Our findings are thus consistent with those reported by
Rivkees et al [18].
High thyroid-stimulating antibody levels before iodine-
131 seem to be associated with a relative resistance to
therapy (24, 26). On the other hand, TRAb levels did
not show any predictive value for iodine-131 therapeutic
outcome [25]. In our present study, pre-treatment
TRAb values were not correlated with iodine-131 thera-
peutic outcome.
In conclusion, thyroid volume progressively diminished
for one year after iodine-131 administration for adoles-
cent GD. Decreases were more significant in hypothyroid
than in non-hypothyroid patients. We also demonstrated
that approximately 90% of patients became hypothyroid
within one year when thyroid volume was less than 50%
of the original volume at 3 months after RAI therapy. We
believe ultrasonographic thyroid volume measurement at
3 months after iodine-131 administration to be clinically
useful for predicting post-treatment hypothyroidism.
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